

Financial Statements and Supplementary Schedule Together with  
Report of Independent Certified Public Accountants

**AMERICAN COMMITTEE FOR THE WEIZMANN  
INSTITUTE OF SCIENCE, INC.**

June 30, 2016

(With Summarized Comparative Information for June 30, 2015)

# AMERICAN COMMITTEE FOR THE WEIZMANN INSTITUTE OF SCIENCE, INC.

## TABLE OF CONTENTS

---

	<b>Page(s)</b>
Report of Independent Certified Public Accountants	1 - 2
Financial Statements:	
Statements of Financial Position as of June 30, 2016 and 2015	3
Statement of Activities for the year ended June 30, 2016, with summarized comparative totals for 2015	4
Statements of Cash Flows for the years ended June 30, 2016 and 2015	5
Notes to Financial Statements	6 - 20
Supplementary Information:	
Schedule of Functional Expenses for the year ended June 30, 2016, with summarized comparative totals for 2015	22



Grant Thornton LLP  
757 Third Avenue, 9th Floor  
New York, NY 10017  
T 212.599.0100  
F 212.370.4520  
[GrantThornton.com](http://GrantThornton.com)  
[linkd.in/GrantThorntonUS](https://www.linkedin.com/company/grantthorntonus)  
[twitter.com/GrantThorntonUS](https://twitter.com/GrantThorntonUS)

## REPORT OF INDEPENDENT CERTIFIED PUBLIC ACCOUNTANTS

To the Board of Directors of  
**American Committee for the Weizmann Institute of Science, Inc.:**

We have audited the accompanying financial statements of American Committee for the Weizmann Institute of Science, Inc. (the “Organization”), which comprise the statement of financial position as of June 30, 2016, and the related statements of activities and cash flows for the year then ended, and the related notes to the financial statements.

### **Management’s responsibility for the financial statements**

Management is responsible for the preparation and fair presentation of these financial statements in accordance with accounting principles generally accepted in the United States of America; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

### **Auditor’s responsibility**

Our responsibility is to express an opinion on these financial statements based on our audit. We conducted our audit in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor’s judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the Organization’s preparation and fair presentation of the financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Organization’s internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

**Opinion**

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of American Committee for the Weizmann Institute of Science, Inc. as of June 30, 2016, and the changes in its net assets and its cash flows for the year then ended in accordance with accounting principles generally accepted in the United States of America.


**Other Matters**

**Supplementary information**

Our audit was conducted for the purpose of forming an opinion on the financial statements as a whole. The Schedule of Functional Expenses for the year ended June 30, 2016 is presented for purposes of additional analysis and is not a required part of the financial statements. Such supplementary information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the financial statements. The information has been subjected to the auditing procedures applied in the audit of the financial statements and certain additional procedures. These additional procedures included comparing and reconciling the information directly to the underlying accounting and other records used to prepare the financial statements or to the financial statements themselves, and other additional procedures in accordance with auditing standards generally accepted in the United States of America. In our opinion, the supplementary information is fairly stated, in all material respects, in relation to the financial statements as a whole.

**Report on 2015 summarized comparative information**

We have previously audited the Organization's 2015 financial statements (not presented herein), and we expressed an unmodified audit opinion on those audited financial statements in our report dated December 17, 2015. In our opinion, the accompanying summarized comparative information as of and for the year ended June 30, 2015 is consistent, in all material respects, with the audited financial statements from which it has been derived.



New York, New York  
December 19, 2016

**AMERICAN COMMITTEE FOR THE WEIZMANN  
INSTITUTE OF SCIENCE, INC.**  
**Statements of Financial Position**  
As of June 30, 2016 and 2015  
(000's omitted)

---

	<u>2016</u>	<u>2015</u>
<b>ASSETS</b>		
Cash and cash equivalents	\$ 24,458	\$ 15,325
Pledges and legacies receivable, net (Note 3)	121,041	114,447
Other assets	1,564	5,456
Investments (Note 4)	523,507	551,773
Office condominium, furniture and equipment, net (Note 5)	<u>7,849</u>	<u>7,467</u>
Total assets	<u>\$ 678,419</u>	<u>\$ 694,468</u>
<b>LIABILITIES AND NET ASSETS</b>		
<b>LIABILITIES</b>		
Accrued expenses and other liabilities	\$ 4,803	\$ 5,767
Due to affiliate (Note 4)	3,177	2,965
Annuity payment liability (Note 2)	8,782	9,552
Loan payable (Note 7)	<u>9,211</u>	<u>8,830</u>
Total liabilities	<u>25,973</u>	<u>27,114</u>
<b>NET ASSETS (DEFICIT)</b>		
Unrestricted	4,424	(37)
Temporarily restricted (Note 9)	159,480	192,269
Permanently restricted (Note 10)	<u>488,542</u>	<u>475,122</u>
Total net assets	<u>652,446</u>	<u>667,354</u>
Total liabilities and net assets	<u>\$ 678,419</u>	<u>\$ 694,468</u>

*The accompanying notes are an integral part of these financial statements.*

# AMERICAN COMMITTEE FOR THE WEIZMANN INSTITUTE OF SCIENCE, INC.

## Statement of Activities

For the year ended June 30, 2016, with comparative totals for 2015  
(000's omitted)

	2016			2015 Total	
	Unrestricted	Temporarily Restricted	Permanently Restricted		Total
<b>REVENUES</b>					
Contributions, exclusive of \$1,893 and \$6,157 in 2016 and 2015, respectively, sent directly to the Weizmann Institute of Science from U.S. donors, net of special events expenses of \$518 and \$524 in 2016 and 2015, respectively.	\$ 12,089	\$ 24,588	\$ 9,792	\$ 46,469	\$ 29,081
Legacies and bequests, exclusive of \$43 and \$245 in 2016 and 2015, respectively, sent directly to the Weizmann Institute of Science from U.S. donors	8,965	5,898	3,628	18,491	8,802
Government and other grants, exclusive of \$5,199 and \$6,677 in 2016 and 2015, respectively, sent directly to the Weizmann Institute of Science from U.S. donors	-	200	-	200	200
Funding from the Institute	1,432	-	-	1,432	8,185
Investment income	267	2,176	-	2,443	2,422
State of Israel incentive interest	-	2,844	-	2,844	2,844
Net realized and unrealized (loss) gain on investments	(1,486)	(15,623)	-	(17,109)	6,280
Net assets released from restrictions	<u>52,872</u>	<u>(52,872)</u>	<u>-</u>	<u>-</u>	<u>-</u>
Total revenues	<u>74,139</u>	<u>(32,789)</u>	<u>13,420</u>	<u>54,770</u>	<u>57,814</u>
<b>EXPENSES</b>					
Program services in support of the Weizmann Institute of Science (including transmissions to the Institute of \$55,608 and \$51,398 in 2016 and 2015, respectively)	55,694	-	-	55,694	51,503
Supporting services:					
Management and general	2,829	-	-	2,829	2,839
Fundraising	9,423	-	-	9,423	9,539
Public information	<u>1,732</u>	<u>-</u>	<u>-</u>	<u>1,732</u>	<u>1,993</u>
Total expenses	<u>69,678</u>	<u>-</u>	<u>-</u>	<u>69,678</u>	<u>65,874</u>
Change in net assets	<u>4,461</u>	<u>(32,789)</u>	<u>13,420</u>	<u>(14,908)</u>	<u>(8,060)</u>
Net assets, beginning of year	<u>(37)</u>	<u>192,269</u>	<u>475,122</u>	<u>667,354</u>	<u>675,414</u>
Net assets, end of year	<u>\$ 4,424</u>	<u>\$ 159,480</u>	<u>\$ 488,542</u>	<u>\$ 652,446</u>	<u>\$ 667,354</u>

The accompanying notes are an integral part of this financial statement.

**AMERICAN COMMITTEE FOR THE WEIZMANN  
INSTITUTE OF SCIENCE, INC.**

**Statements of Cash Flows**

For the years ended June 30, 2016 and 2015

(000's omitted)

	<u>2016</u>	<u>2015</u>
<b>CASH FLOWS FROM OPERATING ACTIVITIES</b>		
Change in net assets	\$ (14,908)	\$ (8,060)
Adjustments to reconcile change in net assets to net cash used in operating activities:		
Depreciation	512	518
Change in the discount and allowance on pledges and legacies receivable	(1,969)	(18,333)
Net realized and unrealized loss (gain) on investments	17,109	(6,280)
Permanently restricted contributions, legacies, and bequests	(13,420)	(8,003)
Changes in assets and liabilities:		
Pledges and legacies receivable	(1,185)	28,257
Other assets	3,892	(2,623)
Accrued expenses and other liabilities	(964)	322
Due to affiliate	212	130
Annuity payment liability	(770)	(230)
Net cash used in operating activities	<u>(11,491)</u>	<u>(14,302)</u>
<b>CASH FLOWS FROM INVESTING ACTIVITIES</b>		
Acquisition of fixed assets	(894)	(147)
Proceeds from sale of investments	37,749	32,497
Purchases of investments	<u>(26,592)</u>	<u>(21,440)</u>
Net cash provided by investing activities	<u>10,263</u>	<u>10,910</u>
<b>CASH FLOWS FROM FINANCING ACTIVITIES</b>		
Proceeds from issuance of loan payable	9,230	-
Payment on principal of loans payable	(8,849)	-
Permanently restricted contributions, legacies, and bequests	13,420	8,003
Change in permanently restricted pledges and legacies receivable	<u>(3,440)</u>	<u>38</u>
Net cash provided by financing activities	<u>10,361</u>	<u>8,041</u>
Net increase in cash	9,133	4,649
Cash, beginning of year	<u>15,325</u>	<u>10,676</u>
Cash, end of year	<u>\$ 24,458</u>	<u>\$ 15,325</u>
<b>SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION</b>		
Cash paid during the year for interest	<u>\$ 374</u>	<u>\$ 521</u>

*The accompanying notes are an integral part of these financial statements.*

**AMERICAN COMMITTEE FOR THE WEIZMANN  
INSTITUTE OF SCIENCE, INC.**  
**Notes to Financial Statements**  
**June 30, 2016**

---

**1. ORGANIZATION**

The American Committee for the Weizmann Institute of Science, Inc. (the “Organization”) was incorporated in New York in 1944. The primary objective of the Organization is to promote, encourage, and advance scientific research and graduate study at the Weizmann Institute of Science (the “Institute”), a world-renowned, scientific research center located in Rehovot, Israel.

The Organization is exempt from federal income taxes under Section 501(c)(3) of the Internal Revenue Code and is designated as a publicly supported organization.

**2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES**

**Basis of Accounting**

The accompanying financial statements have been prepared on the accrual basis of accounting in accordance with accounting principles generally accepted in the United States of America (“US GAAP”).

**Basis of Presentation**

The Organization’s net assets and revenues, gains, and losses are classified based on the existence or absence of donor-imposed restrictions. Accordingly, the net assets of the Organization and changes therein are classified and reported as follows:

*Unrestricted Net Assets* - Net assets that are not subject to donor-imposed stipulations. Unrestricted net assets include those net assets which have been designated by the Board of Directors for specific purposes as well as undesignated amounts.

*Temporarily Restricted Net Assets* - Net assets subject to donor-imposed stipulations that will be met either by actions of the Organization and/or the passage of time.

*Permanently Restricted Net Assets* - Net assets subject to donor-imposed stipulations that will be maintained permanently. Generally, the donors of these assets permit the use of all or part of the income earned on related investments for general or specific purposes.

**Comparative Totals**

The 2016 financial statements are presented with prior year summarized comparative information. With respect to the statement of activities, such information is presented in total, but not by net asset class. Such information does not include sufficient detail to constitute a presentation in conformity with US GAAP. Accordingly, such information should be read in conjunction with the Organization’s financial statements as of and for the year ended June 30, 2015, from which the summarized information was derived.

**Use of Estimates**

The preparation of financial statements in conformity with US GAAP, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

**AMERICAN COMMITTEE FOR THE WEIZMANN  
INSTITUTE OF SCIENCE, INC.**  
**Notes to Financial Statements**  
**June 30, 2016**

---

**Cash and Cash Equivalents**

The Organization classifies deposits in banks and money market accounts with original maturities of three months or less as cash equivalents, excluding cash and cash equivalents available for long-term investment, which are included within investments in the accompanying statements of financial position.

**Contributions, Pledges and Legacies Receivable**

Contributions, including unconditional promises to give (pledges), are reported as revenues in the period received or pledged. Contributions with purpose or time restrictions (defined by management as unrestricted amounts not yet due) are reported as increases in temporarily restricted net assets. When the purpose and/or time restrictions are met, the temporarily restricted net assets are reclassified to unrestricted net assets and reported in the statement of activities as net assets released from restrictions. Contributions subject to donor-imposed restrictions that the corpus be maintained permanently are recognized as increases in permanently restricted net assets.

Conditional promises to give are not recognized until they become unconditional, that is, when the conditions on which they depend are substantially met. Contributions of assets other than cash are recorded at their estimated fair value.

Unconditional promises to give are recorded as contributions at their net present value, less an allowance for uncollectible pledges. Pledges receivable are discounted at credit adjusted rates ranging from 0.76% to 7.05% in 2016 and 2015, respectively. Amortization of the discount is recorded as additional contribution revenue in accordance with donor-imposed restrictions, if any, on the contributions. Legacies are recorded when the will is declared valid, amounts to be received can be reasonably estimated and the probate process is complete.

**Charitable Gift Annuities and Charitable Remainder Trusts**

The Organization enters into agreements with donors to accept and administer charitable gift annuities, which provide for payments to the donors or their beneficiaries based upon specified annuity amounts. Assets held under charitable gift annuities are included in investments. Contribution revenue is recognized at the date the annuity contract is established after recording the liability for the present value of the estimated future payments expected to be made to the donor and/or beneficiary. The liabilities are adjusted annually for changes in the life expectancy of the donor or beneficiary, amortization of the discount, and other changes in the estimates of future payments.

The Organization is the beneficiary of certain charitable remainder trusts that are held and administered by others. The present value of the estimated future cash receipts from these trusts is recognized as an asset and as a contribution when the Organization is notified that the trust has been established.

At June 30, 2016 and 2015, the Organization's annuity payment liabilities were classified as Level 3 within the fair value hierarchy (see Note 4).

**AMERICAN COMMITTEE FOR THE WEIZMANN  
INSTITUTE OF SCIENCE, INC.**  
Notes to Financial Statements  
June 30, 2016

---

The following table summarizes the changes in the Organization's Level 3 annuity payment liability balances for the years ended June 30, 2016 and 2015 (000's omitted):

	<u>Annuities</u>
<b>Balance at June 30, 2014</b>	\$ 9,782
New agreements	306
Payments to annuitants	(1,632)
Terminated agreements	(351)
Change in fair value of annuities payable	<u>1,447</u>
<b>Balance at June 30, 2015</b>	9,552
New agreements	198
Payments to annuitants	(1,190)
Terminated agreements	(521)
Change in fair value of annuities payable	<u>743</u>
<b>Balance at June 30, 2016</b>	<u>\$ 8,782</u>

**Income Taxes**

US GAAP requires that a tax position be recognized or derecognized based on a "more likely than not" threshold. This applies to positions taken or expected to be taken in a tax return. The Organization does not believe its financial statements include any uncertain tax positions for the open tax years. The tax years ended June 30, 2013, 2014, 2015, and 2016 are still open to audit for both federal and state purposes.

**Office Condominium, Furniture, and Equipment**

Furniture and equipment are stated at cost and are being depreciated on a straight-line basis over a range of three to ten years. The office condominium, purchased in 2004, is stated at cost and is being depreciated on the straight-line method over 40 years.

**Functional Allocation of Expenses**

The costs of providing the various programs and other activities of the Organization have been summarized on a functional basis in the statement of activities. Accordingly, certain costs have been allocated among the programs and supporting services benefited.

**Transmissions**

All transmissions made to the Institute for its various projects are made pursuant to authorization by the Executive Committee of the Board of Directors of the Organization. At June 30, 2016 and 2015, the Organization had a liability of approximately \$278,000 and \$98,000, respectively, for amounts authorized before year end that were transferred to the Institute after year end. This amount is included in accrued expenses and other liabilities in the accompanying statement of financial position.

**AMERICAN COMMITTEE FOR THE WEIZMANN  
INSTITUTE OF SCIENCE, INC.**  
**Notes to Financial Statements**  
**June 30, 2016**

---

**Funding from the Institute**

The Institute agreed to assist the Organization with certain operating costs. For the years ended June 30, 2016 and 2015, the Organization received support of approximately \$1,432,000 and \$8,185,000, respectively, which is included in funding from the Institute in the accompanying statement of activities.

**Concentrations of Credit Risk**

Financial instruments that potentially subject the Organization to concentrations of credit risk consist principally of cash and cash equivalents and investments in fixed income funds, equity funds, and alternative investments. The Organization maintains its cash and cash equivalents in various bank accounts that, at times, may exceed federally insured limits. The Organization's cash accounts were placed with high credit quality financial institutions. The Organization has not experienced, nor does it anticipate, any losses in such accounts.

**New Accounting Pronouncements**

In May 2015, Financial Accounting Standards Board issued ASU 2015-07, Disclosures for Investments in Certain Entities That Calculate Net Asset Value per Share (or Its Equivalent). ASU 2015-07 exempts investments measured using the Net Asset Value ("NAV") practical expedient in ASC 820, Fair Value Measurement, from categorization within the fair value hierarchy and related disclosures. Instead, entities are required to separately disclose the information required under ASC 820 for assets measured using the NAV practical expedient. Entities are also required to show the carrying amount of investments measured using the NAV practical expedient as a reconciling item between the total amount of investments categorized within the fair value hierarchy and total investments measured at fair value on the face of the consolidated financial statements. The guidance requires retrospective application and is effective for fiscal years beginning after July 1, 2017. Early adoption is permitted.

Also in 2015, the FASB issued guidance to simplify the presentation of debt issuance costs by requiring debt issuance costs related to a recognized debt liability to be presented as a direct deduction from the carrying amount of that debt liability. The amendments within this update must be applied retrospectively to all periods presented. Early adoption is permitted.

The Organization did not early adopt the new accounting pronouncements and does not believe they will have a material effect on the disclosures in the consolidated financial statements.

**Reclassifications**

Certain reclassifications were made to the fiscal 2015 financial statements in order to conform to the fiscal 2016 presentation. Such reclassifications did not change total assets, liabilities, revenues, expenses or changes in net assets as reflected in the fiscal 2016 financial statements.

**AMERICAN COMMITTEE FOR THE WEIZMANN  
INSTITUTE OF SCIENCE, INC.**  
Notes to Financial Statements  
June 30, 2016

---

**3. PLEDGES AND LEGACIES RECEIVABLE, NET**

At June 30, 2016 and 2015, pledges and legacies receivable consisted of the following (000's omitted):

<u>Amount Due</u>	<u>2016</u>	<u>2015</u>
Within one year	\$ 9,698	\$ 12,416
One to five years	61,821	52,165
More than five years	<u>94,010</u>	<u>96,323</u>
	165,529	160,904
Less:		
Allowance for uncollectible receivables	(15,392)	(14,044)
Discount to present value	<u>(29,096)</u>	<u>(32,413)</u>
	<u>\$ 121,041</u>	<u>\$ 114,447</u>

The Organization is the ultimate beneficiary of certain irrevocable charitable remainder trusts. The value of those trusts is approximately \$11,710,000 and \$11,361,000 as of June 30, 2016 and 2015, respectively, and is included above in gross receivables.

At June 30, 2016 and 2015, the Organization's beneficial interests in its irrevocable charitable remainder trusts were classified as Level 3 within the fair value hierarchy.

The following table summarizes the changes in the Organization's Level 3 irrevocable charitable remainder trusts – which are contained in the Pledges and Legacies Receivable, net balance – for the years ended June 30, 2016 and 2015 (000's omitted):

	<u>Trusts</u>
<b>Balance at June 30, 2014</b>	\$ 12,286
New agreements	300
Terminated agreements	(733)
Unrealized depreciation in fair value	<u>(492)</u>
<b>Balance at June 30, 2015</b>	11,361
Unrealized appreciation in fair value	<u>349</u>
<b>Balance at June 30, 2016</b>	<u>\$ 11,710</u>

Approximately 35% and 40% of the pledges receivable (gross) are due from three donors at June 30, 2016 and 2015, respectively.

**AMERICAN COMMITTEE FOR THE WEIZMANN  
INSTITUTE OF SCIENCE, INC.**  
Notes to Financial Statements  
June 30, 2016

---

**4. INVESTMENTS**

Investments, at fair value, are composed of the following at June 30, 2016 and 2015 (000's omitted):

	<u>2016</u>	<u>2015</u>
Money market funds	\$ 143	\$ 489
Fixed income	1,100	1,174
Mutual funds	525	573
Fund of funds that invest in equity	8,396	9,521
Fund of funds that invest in bonds	4,751	4,922
Weizmann Global Endowment Fund, L.P.	506,346	534,524
Non trading common stock	2,070	-
Common stock	27	24
Other	149	546
	<u>\$ 523,507</u>	<u>\$ 551,773</u>

**Fair Value Measurements**

Fair value is the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. As required by US GAAP for fair value measurement, the Organization uses a fair value hierarchy that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the observable inputs be used when available.

Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from independent sources. Unobservable inputs reflect assumptions that market participants would use in pricing the asset or liability based on the best information available in the circumstances. The hierarchy is broken down into three levels based on the transparency of inputs as follow:

Level 1 - Quoted prices are available in active markets for identical assets or liabilities. A quoted price for an identical asset or liability in an active market provides the most reliable fair value measurement because it is directly observable to the market.

Level 2 - Pricing inputs other than quoted prices in active markets, which are either directly or indirectly observable. The nature of these securities include investments for which quoted prices are available but traded less frequently and investments that are fair valued using other securities, the parameters of which can be directly observed. Also included in Level 2 are investments measured using a NAV per share, or its equivalent, that may be redeemed at that NAV at the date of the statement of financial position or in the near term, which is generally considered to be within 90 days.

**AMERICAN COMMITTEE FOR THE WEIZMANN  
INSTITUTE OF SCIENCE, INC.**  
Notes to Financial Statements  
June 30, 2016

---

Level 3 - Securities that have little to no observable pricing. These securities are measured using management's best estimate of fair value, where the inputs into the determination of fair value are not observable and require significant management judgment or estimation. Also included in Level 3 are investments measured using a NAV per share, or its equivalent, that can never be redeemed at the NAV or for which redemption at NAV is uncertain due to lockup periods or other investment restrictions.

Inputs are used in applying the various valuation techniques and broadly refer to the assumptions that market participants use to make valuation decisions, including assumptions about risk. Inputs may include price information, volatility statistics, specific and broad credit data, liquidity statistics, and other factors. A financial instrument's level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. However, the determination of what constitutes "observable" requires significant judgment by the Organization. The Organization considers observable data to be that market data that is readily available, regularly distributed or updated, reliable and verifiable, not proprietary, and provided by independent sources that are actively involved in the relevant market. The categorization of a financial instrument within the hierarchy is based upon the pricing transparency of the instrument and does not necessarily correspond to the Organization's perceived risk of that instrument.

The following tables summarize investments within the fair value hierarchy as of June 30, 2016 and 2015 (000's omitted):

	<b>2016</b>			
	<b>Level 1</b>	<b>Level 2</b>	<b>Level 3</b>	<b>Total</b>
Money market funds	\$ 143	\$ -	\$ -	\$ 143
Fixed income	-	1,100	-	1,100
Mutual funds	525	-	-	525
Fund of funds that invest in equity	-	8,396	-	8,396
Fund of funds that invest in bonds	-	4,751	-	4,751
Weizmann Global Endowment Fund, L.P.	-	-	506,346	506,346
Non trading common stock	-	-	2,070	2,070
Common stock	27	-	-	27
Other	-	-	149	149
Total	<u>\$ 695</u>	<u>\$ 14,247</u>	<u>\$ 508,565</u>	<u>\$ 523,507</u>

**AMERICAN COMMITTEE FOR THE WEIZMANN  
INSTITUTE OF SCIENCE, INC.**  
Notes to Financial Statements  
June 30, 2016

	2015			Total
	Level 1	Level 2	Level 3	
Money market funds	\$ 489	\$ -	\$ -	\$ 489
Fixed income	-	1,183	-	1,183
Mutual funds	573	-	-	573
Fund of funds that invest in equity	-	9,521	-	9,521
Fund of funds that invest in bonds	-	4,922	-	4,922
Weizmann Global Endowment Fund, L.P.	-	-	534,524	534,524
Common stock	24	-	-	24
Other	-	-	537	537
Total	<u>\$ 1,086</u>	<u>\$ 15,626</u>	<u>\$ 535,061</u>	<u>\$ 551,773</u>

As required by US GAAP for fair value measurement, the following table summarizes the changes in fair values associated with Level 3 assets as of June 30, 2016 and 2015 (000's omitted):

<b>Balance as of June 30, 2014</b>	\$ 538,811
Purchases	16,866
Sales	(26,989)
Realized gain	14,494
Unrealized gain	<u>(8,121)</u>
<b>Balance as of June 30, 2015</b>	535,061
Purchases	24,594
Sales	(36,134)
Realized gain	6,392
Unrealized loss	<u>(21,348)</u>
<b>Balance as of June 30, 2016</b>	<u>\$ 508,565</u>

The Organization used the NAV or its equivalent to determine the fair value of all the underlying investments which (a) do not have a readily determinable fair value and (b) prepare their financial statements consistent with the measurement principles of an investment company or have the attributes of an investment company.

**AMERICAN COMMITTEE FOR THE WEIZMANN  
INSTITUTE OF SCIENCE, INC.**  
Notes to Financial Statements  
June 30, 2016

---

Investments valued at NAV or its equivalent as of June 30, 2016, consisted of the following:

<u>Investment description</u>	<u>Strategy</u>	<u># of Funds</u>	<u>NAV in Funds</u>	<u>Redemption Restrictions/ Liquidity Provisions</u>
Weizmann Global Endowment Fund, L.P.	Long-term capital growth through investments in a diversified portfolio	1	\$506,346,000	Redemptions permitted monthly with restrictions
Fund of funds that invest in equity	Approximate overall performance of MSCI EAFE Index, MSCI Emerging Markets Index, Russel 2000 Index, S&P MidCap 400 Index and Dow Jones U.S. Total Stock Market Index	15	8,396,000	Redemptions permitted daily
Fund of funds that invest in bonds	Approximate overall performance of Barclays Capital U.S. Aggregate Bond Index, U.S. Corporate High Yield 2% Issuer Cap Index and U.S. Treasury Inflation Protected Securities Index	6	4,751,000	Redemptions permitted daily

Investments valued at NAV or its equivalent as of June 30, 2015, consisted of the following:

<u>Investment description</u>	<u>Strategy</u>	<u># of Funds</u>	<u>NAV in Funds</u>	<u>Redemption Restrictions/ Liquidity Provisions</u>
Weizmann Global Endowment Fund, L.P.	Long-term capital growth through investments in a diversified portfolio	1	\$534,524,000	Redemptions permitted monthly with restrictions
Fund of funds that invest in equity	Approximate overall performance of MSCI EAFE Index, MSCI Emerging Markets Index, Russel 2000 Index, S&P MidCap 400 Index and Dow Jones U.S. Total Stock Market Index	15	9,521,000	Redemptions permitted daily
Fund of funds that invest in bonds	Approximate overall performance of Barclays Capital U.S. Aggregate Bond Index, U.S. Corporate High Yield 2% Issuer Cap Index and U.S. Treasury Inflation Protected Securities Index	7	4,921,000	Redemptions permitted daily

The above funds have no unfunded commitments as of June 30, 2016 and 2015.

The Weizmann Global Endowment Fund, L.P. (the "Fund") was formed on November 6, 2002 with the purpose of enabling the Institute and its affiliates to invest on a coordinated basis. The Organization is a limited partner in the Fund. The investment objective of the Fund is to achieve long-term capital growth through investments in a diversified portfolio and to achieve a competitive return over a complete market cycle by allocating the Fund's assets among third-party investment advisers (investment subadvisers) employing a variety of strategies.

**AMERICAN COMMITTEE FOR THE WEIZMANN  
INSTITUTE OF SCIENCE, INC.**  
**Notes to Financial Statements**  
**June 30, 2016**

---

The Fund's investments in common stocks and fixed-income securities are stated at fair value. Fair value of exchange-listed securities is determined by the last sales price on the valuation date. Fixed income securities (other than short-term obligations but including listed issues), are valued based on prices obtained by one or more independent pricing services. Pricing services use a matrix, formula, or other objective methods that take into consideration market indices and yield curves and other specific adjustments.

Mutual funds are valued based on published net asset values. Investment transactions are accounted for on the trade-date basis. Investment income is accounted for on the accrual basis; dividend income is recorded on the ex-dividend date. Realized gains and losses from securities transactions are computed on the average-cost basis and are reported in the statement of activities, net of approximately \$1,100,000 and \$1,400,000 of the Organization's share of related expenses (including the Fund's operating expenses, subadvisor and custodian fees and taxes) for the years ended June 30, 2016 and 2015, respectively.

The Fund's investments in non-registered investment companies are carried at fair value as determined by the General Partner and generally represent the Fund's pro rata interest in the net assets of each non-registered investment company. All valuations utilize financial information supplied by each investment company and are net of management and performance incentive fees or other expenses payable to the investment company managers as required by the investment company agreements.

As a general matter, the fair value of the Fund's investments in non-registered investment companies represents the amount that the Fund can reasonably expect to receive if the Fund's investments were redeemed at the time of valuation based on information reasonably available at the time. The non-registered investment companies provide for periodic redemptions ranging from quarterly to three-year lock-up, except for private equity funds and illiquid shares that cannot be redeemed until the underlying investments are liquidated. Non-registered investment companies generally require advance notice of the Fund's intent to redeem its interest, and may, depending on the non-registered investment company's governing agreements, deny or delay a redemption request. The underlying investments of each non-registered investment company are accounted for at fair value as described in each investment company's financial statements.

The Organization's Board of Directors has authorized a policy permitting the use of total return at a rate of 5% of the fair value of the permanently restricted net assets based on the average of the twelve quarters ended June 30, 2016 and 2015, respectively, for distribution to fund expenditures in accordance with donor restrictions. This policy is designed to preserve the value of these funds in real terms (after inflation) and to provide a predictable flow of funds to support operations.

Investments include amounts held on behalf of the Feinberg Graduate School of the Institute of approximately \$3,200,000 and \$3,000,000 as of June 30, 2016 and 2015, respectively, which are reported as due to affiliate in the statements of financial position, as well as amounts associated with charitable gift annuities of approximately \$14,000,000 and \$16,000,000 as of June 30, 2016 and 2015, respectively. The assets held by the Organization as trustee for its charitable gift annuities include additional amounts set aside by the Organization for state-mandated insurance reserves, which are maintained at the required level.

**AMERICAN COMMITTEE FOR THE WEIZMANN  
INSTITUTE OF SCIENCE, INC.**  
Notes to Financial Statements  
June 30, 2016

The following table summarizes the significant unobservable inputs the organization used to value one investment categorized as Level 3. The table below is not meant to be all inclusive, but instead capture the significant unobservable inputs relevant to determination of fair value at June 30, 2016.

2016			
Assets Type	Fair Value	Valuation Technique	Unobservable Inputs
Voting common shares	\$ 2,070,000	Income approach & Option pricing model	Discount Rate

**5. OFFICE CONDOMINIUM, FURNITURE AND EQUIPMENT, NET**

Office condominium, furniture, and equipment, net consisted of the following at June 30, 2016 and 2015 (000's omitted):

	2016	2015
Office condominium	\$ 10,006	\$ 9,284
Furniture and equipment	1,784	1,762
	11,790	11,046
Less: Accumulated depreciation	(4,056)	(3,694)
	7,734	7,352
Art collection	115	115
	\$ 7,849	\$ 7,467

**6. PENSION PLANS**

The Organization has a defined contribution pension plan which covers substantially all of its employees. Contributions to this plan amounted to approximately \$672,000 and \$626,000 for the years ended June 30, 2016 and 2015, respectively and are based on 9% of an employee's compensation.

At various times, the Organization has entered into deferred compensation agreements with certain key officers. Pursuant to the terms of these contracts and subject to certain conditions, the Organization is required to make periodic payments directly to these executives upon retirement. The assets and liabilities related to these agreements are approximately \$133,000 as of June 30, 2016 and 2015, respectively, and are included in investments and accrued expenses and other liabilities in the accompanying statements of financial position. There were no costs charged to operations related to these agreements for the years ended June 30, 2016 and 2015.

**7. LOAN PAYABLE**

On April 2, 2004, the New York City Industrial Development Agency issued \$8,830,000 of Civic Facility Revenue Bonds (Series A and B) on behalf of the Organization. The proceeds of the Bonds were used to finance the acquisition and renovation of the Organization's principal office, a condominium unit located on the 20<sup>th</sup> floor at 633 Third Avenue, New York, New York, as well as to finance certain issuance costs.

**AMERICAN COMMITTEE FOR THE WEIZMANN  
INSTITUTE OF SCIENCE, INC.**  
**Notes to Financial Statements**  
**June 30, 2016**

---

The 2004 Series A and B bonds were paid off with the proceeds of the 2015 bonds (“Bonds”), issued on October 29, 2015. The 2015 Bonds were issued to take advantage of the significantly lower interest rates offered by the New York City Industrial Agency. In the process of refinancing the 2004 bonds, the Organization incurred \$400,000 in expenses which were financed through the issuance of a \$400,000 note payable (“Note”).

Interest on the Bonds were payable monthly at an annual rate of 3.215%. The Bonds were subject to mandatory redemption by the Organization according to a schedule of annual sinking fund installments commencing on November 1, 2023, and the final payment is due on November 1, 2034.

Interest on the Note is payable monthly at an annual rate of 3.840%. The Note is subject to mandatory redemption by the Organization according to a schedule of annual sinking fund installments commencing on December 1, 2015, and the final payment is due on November 1, 2034.

Interest expense for the years ended June 30, 2016 and 2015 totaled \$374,000 and \$521,000 per annum, respectively.

The Bonds were issued under an Indenture of Trust dated October 1, 2015 by and between the Organization and The Bank of New York, as Trustee, which created a lien on all moneys and securities held by the Trustee for the holders of the Bonds. As further security for the Bonds, the payment of the principal, sinking fund installments, and interest on the Bonds is guaranteed by the Organization pursuant to a Guaranty Agreement, and the Organization assigned to the Trustee certain rights and remedies under the Installment Sale Agreement. The Bonds and Note are further secured by mortgage liens on and security interests in the Organization’s principal office.

**8. COMMITMENTS AND CONTINGENCIES**

At June 30, 2016, the Organization was obligated under non-cancelable operating leases relating to office space through 2020. The minimum future annual commitments under operating leases at June 30, 2016 are summarized as follows (000’s omitted):

<b><u>Year ending June 30:</u></b>	<b><u>Amount</u></b>
2017	\$ 222
2018	218
2019	122
2020	79
2021	81
Thereafter	131
	<u>\$ 853</u>

Rent expense for the years ended June 30, 2016 and 2015 amounted to approximately \$249,000 and \$232,000, respectively.

**AMERICAN COMMITTEE FOR THE WEIZMANN  
INSTITUTE OF SCIENCE, INC.**  
Notes to Financial Statements  
June 30, 2016

---

**9. TEMPORARILY RESTRICTED NET ASSETS**

Temporarily restricted net assets are available for the following purposes at June 30, 2016 and 2015 (000's omitted):

	<u>2016</u>	<u>2015</u>
Purpose restrictions	\$ 140,629	\$ 181,847
Time restrictions	<u>18,851</u>	<u>10,422</u>
	<u>\$ 159,480</u>	<u>\$ 192,269</u>

The purpose-restricted net assets referred to above and the income from permanently restricted net assets at June 30, 2016 and 2015 are available principally for scientific research projects, professorial chairs, scholarships and fellowships, exchange programs, and youth activities.

**10. ENDOWMENT**

The Organization has interpreted the New York Prudent Management of Institutional Funds Act ("NYPMIFA") as requiring the preservation of the original gift, as of the gift date of the donor-restricted endowment funds, absent explicit donor stipulations to the contrary. As a result of this interpretation, the Organization classifies as permanently restricted net assets (a) the original value of the gifts donated to the permanent endowment, (b) the original value of subsequent gifts to the permanent endowment, and (c) accumulations to the permanent endowment made in accordance with the direction of the applicable donor gift instrument at the time the accumulation is added to the fund. The remaining portion of the donor-restricted endowment fund that is not classified in permanently restricted net assets is classified as temporarily restricted net assets until those amounts are appropriated for expenditure by the Organization in a manner consistent with the standard of prudence prescribed by NYPMIFA. In accordance with NYPMIFA, the Board of Directors considers the following factors in making a determination to appropriate or accumulate donor-restricted endowment funds:

- The duration and preservation of the fund
- The purpose of the Organization and the donor-restricted endowment fund
- General economic conditions
- The possible effects of inflation and deflation
- The expected total return from income and the appreciation of investments
- Other resources of the Organization
- The investment policies of the Organization
- When appropriate, alternatives to spending from donor-restricted endowment funds and the possible effects on the Organization

Annual spending from the endowment funds is described in Note 4.

**AMERICAN COMMITTEE FOR THE WEIZMANN  
INSTITUTE OF SCIENCE, INC.**  
Notes to Financial Statements  
June 30, 2016

---

Endowment net asset composition by type of fund as of June 30, 2016 and 2015 follows (000's omitted):

<b>Endowment net asset composition by type of fund as of June 30, 2016</b>	<b>Temporarily Restricted</b>	<b>Permanently Restricted</b>	<b>Total</b>
Donor-restricted endowment funds	\$ 67,412	\$ 488,542	\$ 555,954

<b>Endowment net asset composition by type of fund as of June 30, 2015</b>	<b>Temporarily Restricted</b>	<b>Permanently Restricted</b>	<b>Total</b>
Donor-restricted endowment funds	\$ 106,747	\$ 475,122	\$ 581,869

Changes in endowment net assets for fiscal years 2016 and 2015 are as follows (000's omitted):

	<b>Temporarily Restricted</b>	<b>Permanently Restricted</b>	<b>Total</b>
<b>Endowment net assets, beginning of the year</b>	\$ 106,747	\$ 475,122	\$ 581,869
Contributions and bequests	-	13,420	13,420
Appropriation of endowment assets for expenditure	(25,894)	-	(25,894)
Interest and dividends	2,167	-	2,167
Net realized and unrealized gains	(15,608)	-	(15,608)
Net asset reclassifications	-	-	-
<b>Endowment net assets, end of year</b>	<u>\$ 67,412</u>	<u>\$ 488,542</u>	<u>\$ 555,954</u>

	<b>Temporarily Restricted</b>	<b>Permanently Restricted</b>	<b>Total</b>
<b>Endowment net assets, beginning of the year</b>	\$ 123,287	\$ 467,118	\$ 590,405
Contributions and bequests	-	8,004	8,004
Appropriation of endowment assets for expenditure	(24,961)	-	(24,961)
Interest and dividends	2,623	-	2,623
Net realized and unrealized gains	5,798	-	5,798
Net asset reclassifications	-	-	-
<b>Endowment net assets, end of year</b>	<u>\$ 106,747</u>	<u>\$ 475,122</u>	<u>\$ 581,869</u>

**AMERICAN COMMITTEE FOR THE WEIZMANN  
INSTITUTE OF SCIENCE, INC.**  
**Notes to Financial Statements**  
**June 30, 2016**

---

**11. SUBSEQUENT EVENTS**

The Organization evaluated its June 30, 2016 financial statements for subsequent events through December 19 2016, the date the financial statements were issued. The Organization is not aware of any subsequent events which would require recognition or disclosure in the accompanying financial statements.

**SUPPLEMENTARY INFORMATION**

# AMERICAN COMMITTEE FOR THE WEIZMANN INSTITUTE OF SCIENCE, INC.

## Schedule of Functional Expenses

For the year ended June 30, 2016, with comparative totals for 2015

(000's omitted)

	2016					2015
	Program Services	Management and General	Fundraising	Public Information	Total	Total
Transmissions to the Weizmann Institute of Science	\$ 55,608	-	\$ -	-	\$ 55,608	\$ 51,398
Science programs	-	-	228	-	228	160
Salaries and benefits	78	1,948	6,745	830	9,601	8,969
Professional and consulting fees	-	152	381	351	884	1,605
Travel	1	7	229	4	241	211
Printing, publications and advertising	-	-	343	394	737	822
Occupancy cost (including interest of \$374)	-	234	618	96	948	1,095
Supplies and services	-	95	30	4	129	119
Postage and shipping	-	17	33	9	59	68
Telecommunications	-	29	108	11	148	197
Equipment rental and maintenance	-	95	217	5	317	321
Interest expense	-	-	16	-	16	16
Meetings	-	-	39	-	39	179
Dues, books and subscriptions	-	3	9	26	38	31
Insurance	-	107	-	-	107	99
Depreciation	3	131	381	-	515	518
Other	4	11	46	2	63	66
Total expenses	\$ 55,694	\$ 2,829	\$ 9,423	\$ 1,732	\$ 69,678	\$ 65,874

*This schedule should be read in conjunction with the accompanying financial statements and notes thereto.*